Answer:
Mutations in regulatory proteins during the cell cycle may cause affected cells to divide uncontrollably
Explanation:
Answer:
Explanation:
Using the Mendelian approach to solve this question, we will understand that the mendelian approach has a pattern for inherited traits.
From the data set given, the total number of the population is:
43+9+32+110 = 194
However, their ratio are being calculated as follows:
43/194 = 0.22
9/194 = 0.05
32/194 = 0.16
110/194 = 0.57
After comparison with the Mendelian's approach, we realize that these results seem to be similar to the 9:3:3:1 ratio.
i.e.
3/16 = 0.18
1/16 = 0.06
3/16 = 0.18
9/16 = 0.56
The inheritance pattern obviously dictates that the flax experiment proceeds in the pattern found in the Mendelian's Approach and the resistance of the two different strains were arbitrated by two traits.
Yes and it consists of abiotic factors, river, rocks, etc
If your body lacks enzymes that break down carbohydrates, it would be unable to get sugar molecules for energy production. If you lacked the enzyme to digest proteins, you may not absorb enough amino acids?
<u>Stem cell </u>research has the potential to significantly impact the development of disease-modifying treatments for Parkinson’s disease with considerable progress made in creating dopamine-progressing cells.
Explanation:
Parkinson’s disease, a neurodegenerative disease, leads to reduction of dopamine (a neurochemical messenger which carries messages involving thinking and body movements to brain) in the body because the disease will target and kill dopamine-producing nerve cells (neurons). This leads to loss of movement and thinking abilities which are activated by dopamine.
Stem cells research is done to study about the prospects of stem cells in stem cell therapy for Parkinson’s patients as a viable source of new dopamine nerve cells. Research has been involved in growing stem cells to replace or regenerate dopamine-producing nerve cells by using embryonic stem cells or induced pluripotent stem cells as a treatment modality in Parkinson’s disease.
